Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

$24.99

Common Stock Valuation Ratios (Price Multiples)
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Historical Valuation Ratios (Summary)

Gilead Sciences Inc., historical price multiples (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Price to earnings (P/E)
Price to operating profit (P/OP)
Price to sales (P/S)
Price to book value (P/BV)

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).


The analysis of the financial ratios over the reported periods reveals several notable trends and fluctuations.

Price to Earnings (P/E) Ratio
The P/E ratio demonstrates significant volatility across quarters. Initially, in early 2021, the ratio started at an exceptionally high value of 277.25, rapidly decreasing to more normalized levels between approximately 11 and 30 in the subsequent quarters through the end of 2023. However, starting in early 2024, there is a marked spike with the ratio reaching extreme values such as 166.76, 89.29, and peaking at 925.87 in September 2024, before declining again towards more moderate levels around 20 by mid-2025. This pattern indicates episodic market valuation fluctuations possibly driven by underlying earnings volatility or investor sentiment changes.
Price to Operating Profit (P/OP) Ratio
This ratio displays a broadly similar volatility pattern to the P/E ratio but with comparatively less extreme swings in the initial periods. It fluctuates from a high of 18.31 in early 2021 down to values close to 7-12 throughout 2021 and 2022, followed by an increase to peaks above 140 in late 2024. The P/OP declines again toward mid-2025, settling between 14 and 17. These shifts suggest variations in the market’s assessment of the company's profitability relative to its price, reflecting operating profit changes or stock price volatility.
Price to Sales (P/S) Ratio
The P/S ratio remains relatively stable with moderate fluctuations. Values range mostly between 2.8 and 4.9, with a gradual rising trend observed from late 2023 into 2025, reaching a peak near 5 in late 2024 and early 2025. This indicates a steady or slightly increasing valuation of the company relative to its sales over time, suggesting consistent sales performance with some market optimism in the later periods.
Price to Book Value (P/BV) Ratio
The P/BV ratio exhibits a gradual upward trend over the reported periods. Starting around 4.4 in early 2021, it decreases slightly during mid-2021 but then increases steadily, reaching values above 7 by late 2024, before slightly moderating around 6.4 to 7 in mid-2025. This upward movement could reflect growing market confidence in the company's asset base or improvements in tangible book value perceived by investors.

In summary, the data shows that valuation metrics based on earnings and operating profit experienced pronounced volatility, especially in the 2024 period, indicating possible earnings instability or market speculation. In contrast, price to sales and book value ratios revealed more moderate and sustained increases, suggesting stable sales performance and improving asset valuation over time.


Price to Earnings (P/E)

Gilead Sciences Inc., historical P/E calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
No. shares of common stock outstanding1
Selected Financial Data (US$)
Net income (loss) attributable to Gilead (in millions)
Earnings per share (EPS)2
Share price1, 3
Valuation Ratio
P/E ratio4
Benchmarks
P/E Ratio, Competitors5
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Data adjusted for splits and stock dividends.

2 Q2 2025 Calculation
EPS = (Net income (loss) attributable to GileadQ2 2025 + Net income (loss) attributable to GileadQ1 2025 + Net income (loss) attributable to GileadQ4 2024 + Net income (loss) attributable to GileadQ3 2024) ÷ No. shares of common stock outstanding
= ( + + + ) ÷ =

3 Closing price as at the filing date of Gilead Sciences Inc. Quarterly or Annual Report.

4 Q2 2025 Calculation
P/E ratio = Share price ÷ EPS
= ÷ =

5 Click competitor name to see calculations.


The analysis of the quarterly financial data reveals distinct trends in share price, earnings per share (EPS), and the price-to-earnings (P/E) ratio over the observed periods.

Share Price
The share price demonstrates moderate volatility with an overall upward trajectory. Starting at $66.54, it experienced fluctuations initially, notably rising to $83.50 by the end of 2022. Following a slight decline in early 2023, the price subsequently exhibited a strong upward movement, peaking at $114.31 by the end of 2024. Some correction is observed thereafter, with the price adjusting to approximately $110.28 by mid-2025, indicating continued investor interest and positive market perception over the medium term.
Earnings per Share (EPS)
EPS figures reflect significant variability throughout the period. Early quarters in 2021 show relatively low EPS values starting from $0.24, quickly rising to a peak of $5.89 in September 2021. This is followed by fluctuations ranging mostly between $2.66 and $4.71 through to late 2023, suggesting variable profitability. A sharp decline occurs at the start of 2024 with EPS dropping to $0.10 in the third quarter, indicating a period of reduced earnings performance. Encouragingly, the latter quarters of 2024 and into 2025 reveal a robust recovery, with EPS levels returning to values around $4.8 and above, reflecting improved operational results.
P/E Ratio
The P/E ratio varies widely, driven by the interplay of share price and EPS fluctuations. The ratio starts extremely high at 277.25 in early 2021, decreasing as EPS growth accelerates through September 2021, reaching a more normalized range between approximately 11 and 30 across 2021 to 2023. However, significant spikes are observed in 2024, with the P/E ratio soaring to values such as 925.87 and 296.57, primarily attributable to the sharp decline in EPS during the same period rather than changes in share price. By mid-2025, the P/E ratio stabilizes to a level near 21, suggesting a return to valuation levels more consistent with earnings performance.

In summary, the company's share price exhibits an overall positive trend with periods of volatility, EPS shows variable profitability including a transient downturn followed by recovery, and the P/E ratio reflects these dynamics with considerable fluctuations highlighting changes in market valuation relative to earnings at different times.


Price to Operating Profit (P/OP)

Gilead Sciences Inc., historical P/OP calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
No. shares of common stock outstanding1
Selected Financial Data (US$)
Operating income (loss) (in millions)
Operating profit per share2
Share price1, 3
Valuation Ratio
P/OP ratio4
Benchmarks
P/OP Ratio, Competitors5
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Data adjusted for splits and stock dividends.

2 Q2 2025 Calculation
Operating profit per share = (Operating income (loss)Q2 2025 + Operating income (loss)Q1 2025 + Operating income (loss)Q4 2024 + Operating income (loss)Q3 2024) ÷ No. shares of common stock outstanding
= ( + + + ) ÷ =

3 Closing price as at the filing date of Gilead Sciences Inc. Quarterly or Annual Report.

4 Q2 2025 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= ÷ =

5 Click competitor name to see calculations.


Share Price Trend
The share price demonstrated moderate volatility throughout the observed periods. Beginning at $66.54, it generally increased with some fluctuations, reaching a peak above $114.31 at the end of 2024. Notably, there was a significant rise from approximately $64.92 in Q1 2024 to $114.31 in Q4 2024, followed by some correction to around $110.28 in Q2 2025.
Operating Profit Per Share Behavior
Operating profit per share displayed variability with no clear linear trend. The values fluctuated from a low of $0.66 in Q3 2024 to highs above $9 in the earlier quarters of 2021. A marked dip occurred in the middle of 2024, with the operating profit per share falling below $2 in multiple quarters, before rebounding substantially towards $6.49-$6.61 in mid-2025.
Price to Operating Profit Ratio (P/OP)
The P/OP ratio saw considerable swings, inversely related to the operating profit per share movement. It ranged from single digits early on to an extreme spike reaching 143.05 in Q3 2024, coinciding with the trough in operating profit per share. Following this peak, the ratio declined significantly to under 18 by mid-2025. This pattern suggests periods of high market valuation relative to earnings, especially during the profitability downturns.
Overall Observations
The data exhibits a cyclical behavior in operating profitability impacting market valuation multiples. Despite significant short-term declines in earnings per share during 2024, the share price maintained an upward trajectory over the longer term, indicating investor confidence possibly driven by expectations of recovery or other external factors. The sharp fluctuations in P/OP ratios underscore the sensitivity of market valuations to earnings volatility for the company during the timeframe analyzed.

Price to Sales (P/S)

Gilead Sciences Inc., historical P/S calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
No. shares of common stock outstanding1
Selected Financial Data (US$)
Product sales (in millions)
Sales per share2
Share price1, 3
Valuation Ratio
P/S ratio4
Benchmarks
P/S Ratio, Competitors5
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Data adjusted for splits and stock dividends.

2 Q2 2025 Calculation
Sales per share = (Product salesQ2 2025 + Product salesQ1 2025 + Product salesQ4 2024 + Product salesQ3 2024) ÷ No. shares of common stock outstanding
= ( + + + ) ÷ =

3 Closing price as at the filing date of Gilead Sciences Inc. Quarterly or Annual Report.

4 Q2 2025 Calculation
P/S ratio = Share price ÷ Sales per share
= ÷ =

5 Click competitor name to see calculations.


The analysis of the financial data reveals several key trends over the examined periods related to share price, sales per share, and price-to-sales (P/S) ratio.

Share Price Trends
The share price exhibited an overall upward trajectory from March 2021 to June 2025, although it experienced fluctuations within this timeframe. The price started at $66.54, then saw moderate variations around the low to mid $60s in the first year. There was a notable rise during late 2022, reaching a peak above $83.50 in December 2022. Following this peak, the price faced a downturn toward the end of 2023, dropping to approximately $64.92 by March 2024. Subsequently, the share price surged significantly, reaching a high of $114.31 by December 2024 before slightly retreating but remaining elevated above $98 through mid-2025. This pattern indicates periods of volatility, with a marked improvement in valuation in the latter part of the timeline.
Sales Per Share Trends
Sales per share demonstrated a generally steady and gradual increase throughout the entire period. Beginning at $20.12 in March 2021, sales per share rose consistently, albeit at a modest rate, reaching $23.14 by June 2025. The incremental rises reflect stable revenue performance on a per-share basis, suggesting consistent sales growth or stable sales despite changing market conditions affecting the share price more dramatically.
Price-to-Sales (P/S) Ratio Trends
The P/S ratio showed more pronounced variability compared to sales per share. Starting with a ratio above 3.3 in early 2021, the ratio declined to around 2.84 by mid-2022, indicating a period where the share price was relatively low compared to sales. From mid-2022 onward, the ratio increased sharply, peaking at nearly 5.0 in December 2024. This increase aligns with the surge in share price rather than changes in sales, which were more stable. The elevated P/S ratio in late 2024 and early 2025 suggests heightened market optimism or a premium valuation relative to current sales figures. The ratio experienced slight pulls back after the peak but remained elevated compared to the early periods.

In summary, the financial metrics show that while sales per share steadily improved, the share price and corresponding P/S ratio demonstrated more volatility, with a notable valuation premium emerging in the latter portion of the observed periods. This suggests that market sentiment or other external factors may have driven share price increases beyond what sales growth alone would justify.


Price to Book Value (P/BV)

Gilead Sciences Inc., historical P/BV calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
No. shares of common stock outstanding1
Selected Financial Data (US$)
Total Gilead stockholders’ equity (in millions)
Book value per share (BVPS)2
Share price1, 3
Valuation Ratio
P/BV ratio4
Benchmarks
P/BV Ratio, Competitors5
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Data adjusted for splits and stock dividends.

2 Q2 2025 Calculation
BVPS = Total Gilead stockholders’ equity ÷ No. shares of common stock outstanding
= ÷ =

3 Closing price as at the filing date of Gilead Sciences Inc. Quarterly or Annual Report.

4 Q2 2025 Calculation
P/BV ratio = Share price ÷ BVPS
= ÷ =

5 Click competitor name to see calculations.


The share price of the company exhibits notable fluctuations over the analyzed periods. Initially, the share price hovered in the mid-$60 range during 2021, then experienced a significant rise reaching above $80 by the end of 2022. The price slightly eased in 2023 but maintained levels mostly between $64 and $80. Starting in early 2024, the share price demonstrated a strong upward trend, peaking at $114.31 by the fourth quarter of 2024, before slightly declining yet remaining elevated above $98 through mid-2025.

Book value per share (BVPS) shows a relatively stable trajectory across the entire timeframe. Values consistently ranged between approximately $14 and $18 per share, with some moderate volatility but no extreme changes. The slight dip observed around early 2024 temporarily marked the lowest BVPS in the data set at $14.08, yet it gradually recovered to near previous levels by mid-2025.

The price-to-book value ratio (P/BV) reflects substantial variation correlated with the trends in share price and BVPS. Throughout 2021 and early 2022, the P/BV ratio fluctuated approximately between 3.65 and 4.9, indicating moderate investor valuation relative to book value. However, from mid-2022 onward, P/BV rose sharply, peaking at 7.36 in the fourth quarter of 2024. This rise signifies a growing premium on the company's market price relative to its book value, likely driven by market optimism or expectations for future growth. Despite some pullbacks, the P/BV ratio remained elevated, above 6.4 through mid-2025, suggesting sustained investor confidence and a persistently high valuation multiple.

In summary, the data reveals a company whose market valuation, as represented by share price and P/BV ratio, has strengthened considerably, especially from mid-2022 to late 2024. This increase occurred despite relatively stable book value per share, indicating that market expectations or sentiment have played a significant role in driving equity prices higher. The occasional declines in share price and P/BV ratio denote periods of market adjustment, but the overall trend points to robust investor interest and expanding market valuation over the observed period.